The DNA-helicase HELLS drives ALK− ALCL proliferation by the transcriptional control of a cytokinesis-related program

Annalisa Tameni1,2, Elisabetta Sauta2,3, Valentina Mularoni2, Federica Torricelli2, Gloria Manzotti2, Giorgio Inghirami4, Riccardo Bellazzi3, Valentina Fragliasso2 and Alessia Ciarrocchi2

Abstract

Deregulation of chromatin modifiers, including DNA helicases, is emerging as one of the mechanisms underlying the transformation of anaplastic lymphoma kinase negative (ALK−) anaplastic large cell lymphoma (ALCL). We recently identified the DNA-helicase HELLS as central for proficient ALK− ALCL proliferation and progression. Here we assessed in detail its function by performing RNA-sequencing profiling coupled with bioinformatic prediction to identify HELLS targets and transcriptional cooperators. We demonstrated that HELLS, together with the transcription factor YY1, contributes to an appropriate cytokinesis via the transcriptional regulation of genes involved in cleavage furrow regulation. Binding target promoters, HELLS primes YY1 recruitment and transcriptional activation of cytoskeleton genes including the small GTPases RhoA and RhoU and their effector kinase Pak2. Single or multiple knockdowns of these genes reveal that RhoA and RhoU mediate HELLS effects on cell proliferation and cell division of ALK− ALCLs. Collectively, our work demonstrates the transcriptional role of HELLS in orchestrating a complex transcriptional program sustaining neoplastic features of ALK− ALCL.

Introduction

Anaplastic large cell lymphomas (ALCLs) are a group of neoplasms arising from the transformation of mature T-cell1. The presence of chromosomal rearrangements involving the ALK gene stratifies ALCLs in ALK+ and ALK− identifying two distinct diseases with different clinical behavior and prognosis2–4. ALK− are known to be the most aggressive subtype of ALCL and the life expectancy of affected patients is significantly reduced by the lack of effective therapies5–6. The molecular bases of ALK− ALCLs remain largely unknown as a consequence of the biological complexity of this disease and of its relative rarity that reduces the possibility of extensive profiling7–11. Understanding the mechanisms that underline the development and evolution of ALK− ALCLs is crucial to define the molecular vulnerabilities of these lymphomas and to develop specific therapeutic strategies.

DNA helicases are a class of enzymes whose primary function is to unpack DNA. Considered as molecular motors, these proteins unwind the DNA exploiting ATP hydrolysis, thus facilitating replication and transcription12–14. For their importance in DNA maintenance, repair, and chromosomal segregation, helicases are considered guardian of the genomic stability15,16. Thus, it is not surprising that genetic or transcriptional alterations in many members of this family have been linked to different disease conditions including predisposition to cancer17–20.

Besides, the relevance of these enzymes in promoting transcription initiation and cancer progression, has recently started to emerge as essential mechanism to...
explain their contribution to cell biology. In virtue of their centrality in this fundamental mechanism, helicases are currently counted among the most appealing targets for cancer therapies.

We recently demonstrated that HELLS, a DNA helicase of the SWI/SNF2 family, is required for proficient ALK+ ALCLs proliferation. We showed that HELLS is a downstream target of STAT3 and that its expression is controlled by the ALK− ALCLs specific lncRNA BlackMamba. Besides, we demonstrated that BlackMamba interacts with HELLS driving its positioning on target promoters, suggesting that the role of this helicase in this tumor setting may rely on its transcriptional activity. In this work, we explored in detail the molecular function of HELLS investigating the transcriptional program through which this helicase supports ALK+ ALCLs. We provided evidence that HELLS coordinates the expression of a program of genes involved in cytoskeleton organization and cytokinesis thus orchestrating timing of cell division. We also showed that YY1 is a central partner of HELLS in supporting this program.

Materials and methods

Cell culture and treatments

The human ALK− ALCL cell line MAC2A was a kind gift of Dr. Alain Epstein. The human Breast Implanted Associated (BIA)-ALCL cell line TLBR-2 was a kind gift of Dr. Giorgio Inghirami. The human Breast Cancer and Myeloma (BCMA) cell line 22s14958 was a kind gift of Dr. Alain Epstein. Cell identity was determined yearly. All cell lines were genotyped and routinely tested for Mycoplasma contamination. Cell lines were cultured in RPMI-1640 medium (Gibco) supplemented with 10% FBS at 37 °C in an atmosphere of 5% CO2. MAC2A and TLBR-2 cells were supplemented with IL2 (20U/ml). Viable cells were counted by trypan blue exclusion. Cells were placed 2.5×10^5 cells/ml. For siRNA scramble, we used a Silencer Select negative control (Ambion, Life Technologies). For PAK2 and RHOA we used two different Silencer Selected Pre-designed siRNAs ID:224502, ID: s33826 (Ambion, Life Technologies). For YY1, we used a Silencer Select Validated siRNAs: ID: s14958 (Ambion, Life Technologies)

RNA extraction and quantitative PCR (qRT-PCR)

Total RNA was extracted by TRIzol (Thermo Fisher Scientific) according to the manufacturer’s instructions. One microgram of total RNA was retrotranscribed using the iScript cDNA kit, (Biorad). The amplified transcript level of each specific gene was normalized on CHMP2A housekeeping. ΔΔCt quantification method was used for RT-qPCR analyses. The list of primers used is provided in Supplementary Table 2.

Western blot

Western blot analysis was performed using standard techniques. The primary antibodies were: HELLS (Rabbit mAb#7998, 1:1000 Cell Signaling Technology), γ PAK2 (E-9 Mouse mAb sc-373740, 1:1000 Santa Cruz Biotechnology, Inc), RHOA (26C4 Mouse mAb sc-418, 1:1000 Santa Cruz Biotechnology, Inc), RHOU (Rabbit, PA5-69128, 1:500 Invitrogen), YY1 (Rabbit, D3D4Q, 1:1000, Cell Signaling Technology), β-tubulin antibody (sc-23949, 1:100, Santa Cruz Biotechnology, Inc) and GAPDH (Rabbit mAb#2118, 1:2000, Cell Signaling Technology) All secondary antibodies (rabbit and mouse) were HRP-conjugated (GE Healthcare) and diluted 1:3000. Densitometric analysis was performed using the ImageJ software.

Immunofluorescence (IF)

Cells were spotted on glass slides using Cytospin (Thermo Scientific), fixed with 4% paraformaldehyde for 10 min and permeabilized with 0.1% Triton X-100 for 3 min. Dots were blocked in 1% PBS-BSA solution for 40 min at room temperature and incubated with phalloidin (Alexa Fluor® 488, Thermo Fisher) for actin staining for 50 min. Dots were washed in PBS for three times and nuclei were stained with DAPI. For microtubules staining we used β-tubulin antibody (sc-23949, 1:100, Santa Cruz Biotechnology, Inc)

siRNA transfection

MAC2A and TLBR-2 cells (1×10^6) were transfected with 30 nM siRNA concentration for single KD. SiRNA transfections were performed using the Cell Line Nucleofector Kit SF and Amaxa 4D Nucleofector (program DS-130 for TLBR-2, FI115 for MAC2A). Twenty-four hours after transfection, cells were harvested and plated 2.5 × 105 cells/ml. For siRNA scramble, we used a Silencer Select negative control (Ambion, Life Technologies). For PAK2 and RHOA we used two different Silencer Selected Pre-designed siRNAs ID:224502, ID: s33826 (Ambion, Life Technologies). For YY1, we used a Silencer Select Validated siRNAs: ID: s14958 (Ambion, Life Technologies)

Cell growth and cell division

For cell growth assays, cells were washed with phosphate-buffered saline, seeded at 2.5×10^5 cells/ml and treated with 100 nM doxycycline. Viable cells were counted by trypan blue exclusion.

Plasmids and viral infections

pLKO Tet-On vectors expressing shRNAs against HELLS and lncRNA BlackMamba were generated by cloning synthetic double-stranded oligonucleotides into pLKO Tet-On vector (Addgene #21915). Vectors were packaged into lentiviral particles HEK 293T-cell line and packaged into lentiviral particles HEK 293T-cell line and treated with 100 nM doxycycline. Viable cells were counted by trypan blue exclusion.

Materials and methods

Cell culture and treatments

The human ALK− ALCL cell line MAC2A was a kind gift of Dr. Giorgio Inghirami. The human Breast Implanted Associated (BIA)-ALCL cell line TLBR-2 was a kind gift of Dr. Alain Epstein. Cell identity was determined yearly. All cell lines were genotyped and routinely tested for Mycoplasma contamination. Cell lines were cultured in RPMI-1640 medium (Gibco) supplemented with 10% FBS at 37 °C in an atmosphere of 5% CO2. TLBR-2 cells were supplemented with IL2 (20U/ml).

Doxycycline hyclate was purchased from Sigma and dissolved in H2O.

Cell growth and cell division

For cell growth assays, cells were washed with phosphate-buffered saline, seeded at 2.5×10^5 cells/ml and treated with 100 nM doxycycline. Viable cells were counted by trypan blue exclusion.

Plasmids and viral infections

pLKO Tet-On vectors expressing shRNAs against HELLS and lncRNA BlackMamba were generated by cloning synthetic double-stranded oligonucleotides into pLKO Tet-On vector (Addgene #21915). Vectors were packaged into lentiviral particles HEK 293T-cell line and used for infection of low passages MAC2A or TLBR-2 at multiplicity of infection. Cells were selected with 0.5 or 1 μg/ml of puromycin (MAC2A and TLBR-2 respectively) for 3 days.

The list of shRNAs sequences is provided in Supplementary Table 1.
Immunofluorescences were detected with Nikon Eclipse (Ni) microscope using 60X.

**Chromatin immunoprecipitation (ChiP)**

ChiP was performed as previously described. Chromatin was precipitated with antibodies against HELLS (4ug, Rabbit Polyclonal, orb178580, Biorbyt), YY1 (D3D4Q; 1:100, Cell Signaling Technology), or IgG-isotype control (#66362, Cell Signaling Technology). Each qRT-PCR value was normalized over the appropriate input control and reported in graphs as a relative fold on IgG.

The list of primers used is provided in Supplementary Table 2.

**Co-Immunoprecipitation (Co-IP)**

Cells were collected, crosslinked with 1% formaldehyde for 10 min, treated with 1.25 M glycine for 5 min and resuspended in Buffer A (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5% NP-40) supplemented with protease inhibitor for 8 min in ice. After centrifugation at 3000 rpm for 2 min, the supernatant was collected as the cytoplasmic fraction and used as the quality control of the experiment. The pellet was washed two times with BUFFER B (10 mM HEPES pH7.9, 1.5 mM MgCl2, 10 mM KCl), centrifuged at 3000 rpm for 2 min. Nuclei were resuspended in lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) supplemented with protease inhibitor and kept for 1 h in rotation at 4°C. Nuclei extracts were sonicated using a Bioruptor® Pico sonicator (Diagenode) and centrifuged at 16,000 g for 10 min. Supernatant was kept and was quantified with Bradford. For each experiment, 4 mg of nuclei extracts was used for immunoprecipitation and 150ug was kept as input control. Precoating step was performed using Protein A-Sepharose®-CL-4B beads (GE Healthcare, Sigma Aldrich), HELLS antibody (Rabbit Polyclonal, orb178580, Biorbyt). Preclearing step was performed using total nuclear lysate and Protein A-Sepharose beads for aspecific removal for 1 h in rotation at 4°C. After centrifugation at 500 g for 5 min, we combined the beads from precoating and supernatant from preclearing steps and kept in rotation overnight at 4°C. After centrifugation of 500 g for 5 min, the supernatant was discarded and washed four times with TBS 1X (50 mM Tris-HCl pH 7.4, 150 mM NaCl). Laemmlly Sample Buffer 4x (Biorad) was added to the immunoprecipitad and samples were boiled for 20 min. Co-IP was detected by western blot using the secondary antibody mouse anti-rabbit IgG HRP conjugate (L27A9) (#5127, 1:2000, Cell Signaling Technology).

**Library preparation and RNA-sequencing**

RNA seq libraries were obtained starting from 500 ng of total RNA following Illumina NEXSeq high-output cartridge (double-stranded, reads length 75bp-2 x75).

A sequencing depth of at least 60 million reads for each sample was guaranteed.

Sequencing quality was assessed using the FastQC v0.11.8 software (www.bioinformatics.babraham.ac.uk/projects/fastqc/), showing on average a Phred score per base >34 in each sample. Raw sequences were then aligned to the human reference transcriptome (GRCh38, Gencode release 30) using STAR version 2.7 and gene abundances were estimated with RSEM algorithm (v1.3.1)24. Differential expression analysis was performed using DESeq2 R package25, considering a False Discovery Rate (FDR) of 10% and excluding genes with low read counts. Heatmap representation and unsupervised hierarchical clustering with a complete linkage method were exploited to graphically depict differentially expressed genes (FRD < 0.1).

Significant genes underwent enrichment analysis, performed on Gene Ontology biological processes, KEGG and Reactome pathways databases via enrichR package26, using a significance threshold of 0.05 on p-value adjusted by Benjamini–Hochberg correction for multiple testing.

**Transcriptional factors motif enrichment**

For transcriptional factor motif search, JASPAR 2020 and PROMO (version 3.0.2) software tools were used. A motif similarity threshold of 80% and a dissimilarity level of 15% were respectively applied for JASPAR 2020 and PROMO prediction results.

**Statistical analysis**

Statistical analyses were performed using the GraphPad Prism Software (GraphPad). Statistical significance was determined using Student’s t test. Each experiment was replicated multiple time (>3 up to 6).

**Results**

**HELLS controls ALK− ALCL proliferation by transcriptionally coordinating a panel of cytoskeleton related genes involved in cytokinesis**

To get insight into the transcriptional regulation of HELLS, we performed an RNA-sequencing profiling in TLBR-2 cells which represent the ALK− ALCL subtype known as Breast Implanted Associated (BIA)-ALCL8,27. We generated inducible HELLS knockdown (KD) lines (TLBR-2 HELLSKD) using doxycycline (DOX)-inducible shRNA. HELLS KD was assessed by WB and qRT-PCR (Fig. 1A, B) and functionally validated by the reduction in the expression of already described HELLS-downstream targets28 (Supplementary Fig. 1A). After DOX induction, the gene expression profile of TLBR-2 HELLSKD cells was analyzed and compared to the one obtained from untreated cells used as control. Transcriptional changes
Fig. 1 HELLS transcriptionally controls cytokinesis. A Western blot shows HELLS expression in TLBR-2 HELLS<sup>KD</sup> cells after 48 h of doxycycline (DOX) induction. GAPDH was used as housekeeping gene. B qRT-PCR analysis of HELLS expression in TLBR-2 HELLS<sup>KD</sup> cells after 48 h of doxycycline induction. The values represent mean ± SEM (n = 3) *p < 0.05; **p < 0.01. C The heatmap depicts hierarchical clustering based on the 728 differentially expressed genes, whose read counts are Z-score normalized. Unsupervised hierarchical clustering was performed between DOX and CTRL samples (as indicated by the colored bar on columns) with a complete linkage method. Color intensity for each gene shows Z-score values ranging from red for upregulation and green for downregulation. D Most significant enriched pathways (adjusted p-value < 0.05) are represented showing the number of DE genes mapped in each considered pathway. E The heatmap depicts validated significantly downregulated genes. Green color bar shows fold difference on Log<sub>2</sub> scale calculated between DOX and CTRL samples. Darker green represents the most downregulated genes. Genes in red were selected for further validations. F Immunofluorescence images of TLBR-2 HELLS<sup>KD</sup> cells and MAC2A HELLS<sup>KD</sup> cells after 48 h of doxycycline (DOX) induction. Cells were stained with DAPI, F-actin, and β-tubulin antibodies. The white scale bar represents 10 μm.
observed after HELLS\textsuperscript{KD} revealed 728 differentially expressed genes. 413 were downregulated and 315 were upregulated upon HELLS\textsuperscript{KD} with a FDR < 0.1 (Fig. 1C). Gene ontology analysis of HELLS-target genes revealed the enrichment of several categories including cell cycle, DNA damage, histone modification, and chromatin organization. Noticeably, top scoring in this list, there were multiple Rho GTPases and cytoskeleton related categories, including cytoskeleton regulation by Rho GTPases and Rho GTPases signaling (Fig. 1D, E). This was particularly interesting since we previously reported that the reduced cellular proliferation displayed by ALK\textsuperscript{−}ALCL upon HELLS loss is associated with defects in cytokinesis and a marked increase in multi-nucleated cells of which Rho-GTPases are major players\textsuperscript{8}.

To give a phenotypic readout to these results, we evaluated the organization of cytoskeleton in T-cells\textsuperscript{29} performing immunostaining for β-tubulin (as a principal constituent of microtubules) and for F-actin upon HELLS\textsuperscript{KD} in TLBR-2 and in an additional cell line representing the systemic ALK\textsuperscript{−}ALCL subtype (MAC2A) (Supplementary Fig. 1B, C). Although we did not observe differences in the quantity of β-tubulin (Supplementary Fig. 1D), a less organized localization of β-tubulin in the midzone of central spindle was detected in HELLS\textsuperscript{KD} cells as compared to control cells (Fig. 1F). By contrast, we observed a profound reorganization of the F-actin with a reduced alignment and compaction in cleavage furrow structure. This phenomenon resulted in an incomplete actomyosin ring formation in HELLS\textsuperscript{KD} cells as compared to control cells (Fig. 1F), in agreement with the multi-nucleated phenotype previously reported\textsuperscript{8}.

Together, these results indicate that, in ALK\textsuperscript{−}ALCL, HELLS contributes to an appropriate cytokinesis via the transcriptional control of genes involved in contractile ring regulation.

**HELLS controls cytokinesis by directly binding to target gene promoters**

Using RT-qPCR, we validated a representative set of altered genes involved in cytoskeleton and cytokinesis confirming the RNA-sequencing results and the effect of HELLS KD on these processes (Fig. 2A, Supplementary Fig. 2A). Since we showed that HELLS cooperates with the IncRNA BlackMamba for transcriptional activity in ALK\textsuperscript{−}ALCL and concurs to the IncRNA BlackMamba pro-oncogenic role in these cells\textsuperscript{8}, we investigated whether IncRNA BlackMamba was involved in the HELLS-dependent regulation of these genes. Taking advance of the previously generated TLBR-2 and MAC2A BlackMamba\textsuperscript{KD} inducible cell lines\textsuperscript{8}, we showed that silencing of this IncRNA resulted in an important reduction of all tested HELLS-target genes (Fig. 2B, Supplementary Fig. 2B, C) confirming the functional synergy between BlackMamba and HELLS and further indicating the cytokinesis related genes as a central node of the transcriptional program supported by this axis in ALK\textsuperscript{−}ALCL.

To further investigate the direct role of HELLS in the regulation of these genes, we performed ChIP experiments to assess the binding of HELLS on their promoters. We observed a significant and specific enrichment of HELLS binding on 10 out of 11 promoter regions tested in both MAC2A and TLBR-2 cells (Fig. 2C). These data confirm that HELLS acts as a transcriptional activator of these genes.

**YY1 is a transcriptional partner of HELLS in ALK\textsuperscript{−}ALCL**

Little is still known on the transcriptional function of helicases. Thus, to explore how HELLS controls the expression of its target genes we searched for putative transcriptional factors (TFs) able to cooperate with HELLS in ALK\textsuperscript{−}ALCL. A region spanning 500 bp around the transcriptional starting site (TSS) of each HELLS-target gene was selected (Fig. 3A). A prediction search for TF binding sites enriched in these regions was performed using JASPAR\textsuperscript{30} and PROMO\textsuperscript{31} tools. 607 TFs and 26 TFs were significantly identified by JASPAR and PROMO, respectively. Merge of these lists resulted in a final list of 9 top scoring TFs and HELLS potential co-factors (predicted to bind up to 90% of the promoters regions used in this search): Yin Yang 1(YY1), Transcription Factor AP-2 Alpha (TFAP2A), Sp1 transcriptional factor (SP1), Nuclear Factor 1C (NFIC), MYB Proto-Oncogene Transcription Factor (MYB), Forkhead Box P3 (FOX3P), ETS Proto-Oncogene 1 (ETS1), ETS Transcription Factor ELK1 (ELK1) and E2F Transcription Factor 1(E2F1) (Fig. 3B, C).

To validate this analysis, we first tested the basal expression of each of these TFs in ALK\textsuperscript{−}ALCL cell lines. 7 out of 9 (78%) TFs were expressed in all tested cell lines even if with variable levels. By contrast, no expression was observed for FOXP3 and SP1 (Fig. 3D).

Next, we investigated the potential interaction of these factors with HELLS by co-immunoprecipitation experiments in nuclear extracts. Among all the TFs investigated, only YY1 was found to interact with HELLS in both TLBR-2 and MAC2A cells (Fig. 3E), although the levels of YY1 in MAC2A cells are significantly lower than in TLBR2. To enforce the idea of cooperation between HELLS and YY1, we performed ChIP assay to investigate the binding of YY1 on the promoter regions of HELLS-target genes both in MAC2A and TLBR-2 cell lines. We showed that 80% of the tested promoter (9/11) were simultaneously bound by both factors supporting the hypothesis of a functional cooperation between these two factors (Fig. 3F). To establish a hierarchy within their relationship, we analyzed how HELLS KD affects YY1 binding on target promoters. Noticeably, YY1 was
dissplaced by these regions in the absence of HELLS while no perturbation of YY1 expression levels was detected upon HELLS KD (Fig. 3F, Supplementary Fig. 3A) indicating that HELLS is crucial in positioning YY1 on specific target genes in the context of ALK−ALCL.

YY1 cooperates with HELLS to foster the transcription of cytokinesis-related genes

YY1 is an ubiquitous transcriptional factor known to have a fundamental role in normal and cancer-related processes. Thus, to consolidate its role as HELLS partner in the transcriptional program of ALK−ALCL, we silenced YY1 with specific siRNA. WB analyses and qRT-PCR confirmed the efficiency of the silencing (Fig. 4A, B). Parallel analysis demonstrated that previously reported YY1 target genes were coherently altered upon its KD (Supplementary Fig. 3B, C). Proliferation analysis of TLBR2 and MAC2A transfected with either siRNA against YY1 or scramble oligos as control did not evidence a significant effect on cell proliferation (Fig. 4C). However, we observed a significant increase in the number of multinucleated cells in YY1KD (Fig. 4D, E).
Fig. 3 HELLS interacts with the transcriptional factor YY1. A Schematic representation of CDC42SE2 genomic locus showing the position, the level of transcription and the enrichment of H3K4me3 on its putative promoter. B The Venn diagram represents the intersection between transcriptional factors (TFs) identified by JASPAR (n = 607) and PROMO (n = 26) TFs binding prediction tools. The intersection shows the number of HELLS-predicted and common TFs (n = 9). C JASPAR and PROMO similarity scores are represented for top-ranked enriched transcription factors (TFs). D qRT-PCR analysis of top scoring TFs in TLBR-2 and MAC2A cell lines. Each data represent mean ± SEM (n = 3). E Nuclear extract from TLBR-2 and MAC2A cells were tested for the presence of a multi-protein complex. Co-immunoprecipitation experiments were performed to evaluate binding of HELLS to YY1. Western blots are representative of two independent experiments. F ChIP qRT-PCR detection of YY1 in TLBR-2 HELLSKD and MAC2A HELLSKD after 48 h of doxycycline (DOX) induction. KLF4 and α-satellite were used as positive and negative controls, respectively. The values represent the fold enrichment over IgG (representative of three independent experiments).
Fig. 4 YY1 cooperates with HELLS to regulate the multi-nucleated phenotype. A Western Blot shows the knockdown of YY1 36 h post-nucleofection with a specific siRNA in TLBR-2 and MAC2A. GAPDH was used as housekeeping gene. B qRT-PCR analysis of YY1 expression after siRNA in TLBR-2 and MAC2A cell lines (36 h post-nucleofection). Each data represent mean ± SEM (n = 3). Two-tailed t-test. **p < 0.01. C The graph represents the relative growth curve of TLBR-2 and MAC2A 72 h post-nucleofection with YY1 specific siRNA. Data were normalized on siRNA scramble values. Each data point represents the mean ± SEM (n = 3). Two-tailed t-test. D The panels show the percentage of multi-nucleated cells in at least 500 cells stained with β-tubulin and F-actin antibodies (48 h post-nucleofection). Each data point represents the mean ± SEM (n = 3). Two-tailed t-test. *p < 0.05; **p < 0.01. E Panels show representative immunofluorescences of TLBR-2 and MAC2A stained with DAPI, F-actin, and β-tubulin antibodies 48 h post-nucleofection. The scale bar represents 10 μm. F qRT-PCR analysis of a panel of selected HELLS-target genes in TLBR-2 and MAC2A 36 h post-nucleofection with specific YY1 siRNA. The values represent mean ± SEM (n = 3). Two-tailed t-test. *p < 0.05; **p < 0.01.
Coherently, silencing of YY1 was associated with repression of RHOU, PAK2, PLK1, AURKB, PITPNM1, CDC42SE2, KLHL21, and KIF20A (Fig. 4F). This was in line with a positive cooperation of YY1 and HELLS in the regulation of cytokinesis genes and with the observed increase in multi-nuclei. Intriguingly, YY1 did not affect RHOA expression suggesting that other factors participate to HELLS transcriptional regulation of ALK− ALCLs. The involvement of other transcriptional partners likely accounts for the fact that YY1KD only partially recapitulates HELLSKD phenotype.

**Downstream effects of HELLS are mediated by multiple Rho-GTPases and effectors**

Rho-GTPases are a family of small GTPase proteins involved in many aspects of intracellular actin dynamics including cell division. During the cytokinesis, Rho-GTPases trigger the initiation of the cleavage furrow from which cytosol division begins. Rho-GTPases are also known for their role in the regulation of cell growth and proliferation and cytoskeleton rearrangements in T-lymphomas. Thus, we knocked down the expression of RhoA, RhoU, and Pak2 with specific siRNAs. Since Rho-GTPases are known to work in a highly cooperative manner, we also combined siRNAs to simultaneously knockdown two or more of these proteins. Figures 5A and 5B show the efficiency of the silencing at the mRNA and protein level in both MAC2A and TLBR-2 cells.

We noticed that while RhoAKD or Pak2KD did not alter the expression of the others, RhoU KD exerted a significant effect on RhoA expression, suggesting a tight interplay between these two proteins. Morphologically, RhoAKD and RhoUKD led to the increase in the percentage of multi-nucleated cells relative to siRNA scramble. By contrast, no such effect was observed for Pak2 silencing. This phenomenon slightly increased when RhoAKD and RhoUKD were combined. On the contrary, combined RhoUKD/Pak2KD and RhoAKD/Pak2KD did not increase the percentage of multi-nucleated cells relative to RhoUKD and RhoAKD, respectively. Consistently, triple KD resulted in an induction of multinuclei comparable to combined RhoAKD/RhoUKD or RhoAKD (Fig. 5C). To assess if the multi-nucleated phenotype resulted from cytokinesis failure, we quantified cytokinetic cells by immunofluorescence using F-actin and β-tubulin staining. A significant decrease in the percentage of total cytokinetic cells and a relative increase in abnormal cytokinetic cells were observed in single and combined RhoAKD/RhoUKD compared to siRNA scramble (Fig. 5D).

Immunofluorescences showed that both RhoAKD and RhoUKD affected β-tubulin organization at central spindles or midbody structures. The proper F-actin organization at contractile ring was also dramatically affected resulting in an abnormal formation of cleavage furrow (Fig. 5E). As expected, combined RhoAKD and RhoUKD resulted in a more pronounced phenotype close to the one obtained with HELLSKD (Fig. 5E).

The analysis of cell proliferation was coherent with these observations. Single silencing of RhoU and Pak2 did not affect significantly cell growth while a significant decrease in cell proliferation was observed in RhoAKD in both cell models. Combined RhoUKD/RhoAKD resulted in a cell proliferation reduction similarly to single RhoAKD whereas combined RhoUKD/Pak2KD enhanced the effects of single RhoUKD and Pak2KD but only in TLBR-2. Notably, triple KD resulted in a significant decrease in cell proliferation, but this reduction was similar to RhoAKD or RhoUKD/Pak2KD (Fig. 5F). Collectively, these data demonstrated that RhoA and RhoU mediate HELLS effects on cell proliferation and cell division of ALK− ALCLs and that RhoA has a prominent role in this process.

**Discussion**

Aberrant expression of epigenetic modifiers fostering the transcriptional program of neoplastic T-cells is emerging as a common feature and potential vulnerability of ALK− ALCLs. In line with this evidence, here we showed that the DNA-helicase HELLS supports ALK ALCL proliferation by controlling a gene expression program that is functional for the execution of cytokinesis and therefore for proficient cell division (Fig. 6).

HELLS is a multifunctional protein proved to play, among the others, critical roles in DNA methylation, chromatin packaging, and development of lymphoid tissue. Known also as Lymphoid-specific helicase (Lsh) HELLS is required for normal development and survival of lymphoid and other tissues via chromatin organization, promotion of DNA double-strand break repair, and chromatin accessibility modification. In cancer, HELLS is deregulated in several settings i.e. gliomas, retinoblastoma, prostate, breast carcinomas, medulloblastoma, leukemia, where it promotes cellular proliferation and stemness. A significant part of HELLS activity in these processes is mediated by its transcriptional function. The way through which HELLS controls gene expression is still partially undefined. Its interaction with epigenetic silencers including G9a and DNMTs as well as with transcriptional factors like E2F3 and c-Myc has been described. Here, we added an additional part of information showing that in the specific context of ALK− ALCL, HELLS interacts
and functionally cooperates with the transcription factor YY1. We demonstrate that DNA binding motif for YY1 is enriched within the HELLS binding sites and that these two factors physically interact and co-occupy the same regions at the level of target promoters to ensure transcription of a large set of cytokinesis-related genes.
YY1 is an ubiquitously expressed transcriptional factor with a fundamental role in embryogenesis, adult hematopoiesis, differentiation, replication, and cellular proliferation. YY1 ensures the proper completion of mitosis and its knockdown leads to defects in cytokinesis and accumulation of multi-nucleated cells. YY1 is often deregulated in hematopoietic malignancies where it controls the survival and growth of neoplastic cells.

Coherently, here we reported that in ALK^- ALCL loss of YY1 is associated with accumulation of multi-nucleated cells likely attributable to incomplete cytokinesis.

The functional relationship between HELLS and YY1 has never been described before. Interestingly, we showed that the loss of HELLS leads to YY1 displacement from DNA. This seems to indicate that HELLS, by altering chromatin accessibility, works by priming the binding of specific transcription factors to target promoters therefore regulating specific set of context specific genes.

By RNA-sequencing profiling we showed that a significant part of the HELLS transcriptional program in ALK^- ALCL converges on the regulation of cytoskeleton and cytokinesis. To the best of our knowledge this is the first time that the transcriptional activity of HELLS is linked to these biological processes.

Cytoskeleton is the structure responsible for cell shape maintenance and organization. It also confers mechanical support to every cellular process from proliferation and division to cell migration, adhesion, and interaction with the surrounding microenvironment.

Of note, recent genetic and molecular profiling studies have unveiled a critical role of cytoskeleton during transformation and progression of T-cells. Although we still lack of a definitive overall view of how cytoskeleton change during lymphomagenesis, the emerging picture suggests that the cytoskeleton transcends the maintenance of cell morphology and polarity providing a more complex support to T-cells in the response to intrinsic and environmental clues.

Among HELLS-downstream effectors, we identified several Rho-GTPases and their related proteins including RhoA, RhoU, and Pak2. Single and combined KDs of these proteins highlight that RhoA and RhoU are key effectors of HELLS program controlling both cell proliferation and cell division.

RhoA is a key player in T-cell processes and its deregulation has emerged as a central issue of T-lymphoma biology. Coherently, our results demonstrate that RhoA is a fundamental effector of HELLS-dependent oncogenic program. At the transcriptional level, RhoA results regulated by HELLS but not by YY1 suggesting a more complex regulation of this Rho-GTPase in this setting. Limited information are available on the regulation of RhoA, and given its centrality, additionally studies are needed to better clarify this point.

As RhoU can mediate the effects of WNT and STAT3 signaling pathways in regulating cell morphology, cytoskeletal organization, and proliferation, our data
provide a new layer of complexity demonstrating a new role of RhoU in cytokinesis via the STAT3-BlackMamba-HELLS axis.

The cooperative role of Rho-GTPases in the execution of neoplastic program driven by HELLS is in agreement with their fundamental role in the regulation of cell proliferation, cell division, and actin polymerization in cancer.

Collectively, our data provide novel insights into the mechanism sustaining the progression of ALK-ALCL via the untapped role of HELLS as transcriptional regulator of cytokinesis. Since HELLS is expressed in many tumors and plays a relevant role in the transcription and genomic stability of cancers, its pharmacological inhibition may represent a promising therapeutic strategy in lymphomas and in other human neoplasms.

Acknowledgements
The authors are grateful to Marina Grassi for technical help.

Author details
1Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena 41125, Italy. 2Laboratory of Translational Research, Azienda USL-IRCSS di Reggio Emilia, Reggio Emilia 42123, Italy. 3Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Via Ferrata 5, 27100 Pavia, Italy. 4Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA

Author contributions
A.T. designed research and performed experiments, E.S. performed bioinformatics analysis, V.M. and G.M. analyzed data, F.T. prepared samples for sequencing, R.B. supervised bioinformatics analyses, G.I. contributed to data analyses, V.F. and A.C. designed research, supervised experiments, and wrote the manuscript.

Data availability
Raw data files of RNA-sequencing have been deposited in EMBL-EBI ArrayExpress and are accessible through the accession number E-MTAB-9918.

Ethics statement
This research does not involve animal or other human subjects.

Funding
This work was funded by Ministero della Salute (Ricerca Finalizzata No. GR-2016-02364298, V.F.).

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-03425-0.

Received: 23 October 2020 Revised: 11 January 2021 Accepted: 12 January 2021
Published online: 27 January 2021

References
1. Swerdlow, S. H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375–2390 (2016).

2. Morris, S. W. et al. Fusion of a kinase gene, ALK, to a nuclear protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263, 1281–1284 (1994).

3. Hapgood, G. & Savage, K. J. The biology and management of systemic anaplastic large cell lymphoma. Blood 126, 17–25 (2015).

4. Parrilla Castellar, E. R. et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124, 1473–1480 (2014).

5. Ferreri, A. J., Govi, S., Pileri, S. A. & Savage, K. J. Anaplastic large cell lymphoma, ALK-negative. Crit. Rev. Oncol. Hematol. 85, 206–215 (2013).

6. Savage, K. J. et al. ALK- anaplastic large cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111, 5496–5504 (2008).

7. Crescenzo, R. et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 27, 516–532 (2015).

8. Fragliasso, V. et al. The novel IndcRNA BlackMamba controls the neoplastic phenotype of ALK(-) anaplastic large cell lymphoma by regulating the DNA helicase HELLS. Leukemia 34, 2964–2980 (2020).

9. Scarfo, I. et al. Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. Blood 127, 221–232 (2016).

10. Hasler, M. R. et al. Insight into the pathogenesis of anaplastic large-cell lymphoma. Nat. Rev. Cancer 17, 596–608 (2016).

11. Luchtel, R. A. et al. Recurrent M5C (E1190) mutations in ALK-negative anaplastic large cell lymphoma. Blood 133, 2776–2789 (2019).

12. Singleton, M. R., Dillingham, M. S. & Wigley, D. B. Structure and mechanism of the cooperative role of Rho-GTPases in the execution of neoplastic program driven by HELLS is in agreement with their fundamental role in the regulation of cell proliferation, cell division, and actin polymerization in cancer.

13. Abdel-Monem, M. & Hoffmann-Berling, H. Enzymic unwinding of DNA. 1. Helicases and nucleic acid translocases. Eur. J. Biochem. 65, 431–440 (1976).

14. Lohman, T. M., Tomkova, E. J. & Wu, C. G. Non-hexameric DNA helicases and translocases mechanisms and regulation. Nat. Rev. Mol. Cell Biol. 9, 391–401 (2008).

15. Larsen, N. B. & Hickson, I. D. RecQ helicases: conserved guardians of genomic integrity. Adv. Exp. Med. Biol. 767, 161–184 (2013).

16. Brosh, R. M. Jr. DNA helicases involved in DNA repair and their roles in cancer. Nat. Rev. Cancer 13, 542–558 (2013).

17. Chan, E. M. et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature 568, 551–556 (2019).

18. Deans, A. J. & West, S. C. DNA interstrand crosslink repair and cancer. Nat. Rev. Cancer 11, 467–480 (2011).

19. Levran, O. et al. The BRCA1-interacting helicase BRIP1 is de ned: report from the International Peripheral T-cell Lymphoma Project. Blood 111, 5496–5504 (2008).

20. Thijssen, P. E. et al. Mutations in CDCA7 and HELLS cause immunode ciency aberrant levels of ERBB4 transcripts. Blood 127, 221–232 (2016).

21. Dobin, A. et al. STAR ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).

22. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform. 12, 323 (2011).

23. Love, M. I., Huber, W. & Anders, S. Moderating estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).

24. Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucelic Acids Res. 44, W90–W97 (2016).

25. Lechner, M. G. et al. Survival signals and targets for therapy in breast implant-associated ALK-anaplastic large cell lymphoma. Clin. Cancer Res. 18, 4549–4559 (2012).

26. von Eyss, B. et al. The SNPf2-like helicase HELLS mediates EZF3-dependent transcription and cellular transformation. Embo J. 31, 971–985 (2012).

27. Billadeau, D. D., Nolt, J. C. & Gomez, T. S. Regulation of T-cell activation by the cytoskeleton. Nat. Rev. Immunol. 7, 131–143 (2007).

28. Fornes, O. et al. JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucelic Acids Res. 48, D287–D292 (2020).

29. Messegueur, X., Escudero, R., Farre, D., Nunez, O., Martinez, J. J. & Alba, M. M. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 18, 333–334 (2002).

Official journal of the Cell Death Differentiation Association
32. Liu, Z. et al. Polycomb Group Protein YY1 is an essential regulator of hematopoietic stem cell quiescence. *Cell Rep.* **22**, 1545–1559 (2018).
33. Morales-Martinez, M. et al. Regulation of Kruppel-Like Factor 4 (KLF4) expression through the transcription factor Yin-Yang 1 (YY1) in non-Hodgkin B-cell lymphoma. *Onco Targets Ther.* **10**, 2173–2189 (2016).
34. Riggio, K. J. et al. Yin-yang 1 activates the c-myc promoter. *Mol. Cell. Biol.* **13**, 7467–7495 (1993).
35. Lin, J. H., Yen, J. C., Yang, B. & Ou, Q. A critical role of transcription factor YY1 in rheumatoid arthritis by regulation of interleukin-6. *J. Autoimmun.* **77**, 67–75 (2017).
36. Liu, Z. & Wiener, O. D. Positioning the cleavage furrow: All you need is *Rho*. *J. Cell Biol.* **213**, 605–607 (2016).
37. Chirico, M. Rho GTases as regulators of mitosis and cytokinesis in mammalian cells. Small *GTPases* **5**, e29770 (2014).
38. Miller, A. L. & Bement, W. M. Regulation of cytokinesis by Rho GTPase flux. *Nat. Cell Biol.* **11**, 71–77 (2009).
39. Piekny, A., Werner, M. & Glotzer, M. Cytokinesis: welcome to the Rho zone.
40. Voena, C. & Chiare, R. RHO family GTases in the biology of lymphoma. *Cell Death and Disease* **39**, 113 (2016).
41. Guo, F., Cancelas, J. A., Hildeman, D., Williams, D. A. & Zheng, Y. Rac GTPase isoforms Rac1 and Rac2 play a redundant and crucial role in T-cell development. *Blood* **112**, 1767–1775 (2008).
42. Choudhari, R. et al. Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice. *Blood* **127**, 1297–1306 (2016).
43. Dumont, C. et al. Rac GTases play critical roles in early T-cell development. *Blood* **113**, 3990–3998 (2009).
44. Lens, S. M. A. & Medema, R. H. Cytokinesis defects and cancer. *Nat. Rev. Cancer* **19**, 32–45 (2019).
45. Geiman, T. M. & Muegge, K. Lsh an SNF2/helicase family member, is required for proliferation of mature T lymphocytes. *Proc. Natl Acad. Sci. USA* **97**, 4772–4777 (2000).
46. Zhi, H. et al. Lsh is involved in de novo methylation of DNA. *EMBO J.* **25**, 335–345 (2006).
47. Baumann, C., Ma, W., Wang, X., Kandasamy, M. K., Viveiros, M. M. & De La Fuente, R. Helicase LSH/Hells regulates kinetochore function, histone H3/Thr3 phosphorylation and centromere transcription during oocyte meiosis. *Nat. Commun.* **11**, 4486 (2020).
48. He, Y. et al. Lsh/HELLS is required for B lymphocyte development and immunoglobulin class switch recombination. *Proc. Natl Acad. Sci. USA* **117**, 20100–20108 (2020).
49. Sipruce, C. et al. HELLS and PRDM9 form a pioneer complex to open chromatin at mitotic recombination hot spots. *Genes Dev.* **34**, 398–412 (2020).
50. Lave, C. T. et al. HELLS regulates chromatin remodeling and epigenetic silencing of multiple tumor suppressor genes in human hematopoietic carcinoma. *Hepatology* **69**, 2013–2030 (2019).
51. Ren, J., Finney, R., Ni, K., Carr, M. & Muegge, K. The chromatin remodeling protein Lsh alters nucleosome occupancy at putative enhancers and modulates binding of lineage specific transcription factors. *Epigenetics* **14**, 277–293 (2019).
52. Zhang, G. et al. Chromatin remodeler HELLS maintains glial stem cells through EZF3 and MYC. *JCI Insight* **4**, e126140 (2019).
53. Benavente, C. A., Finkelstein, D., Johnson, D. A., Marine, J. C., Ashery-Padan, R. & Dyer, M. A. Chromatin remodelers HELLS and UHRF1 mediate the epigenetic deregulation of genes that drive retinoblastoma tumors progression. *Onco Targets Ther.* **5**, 9594–9608 (2014).
54. Zocchi, L. et al. Chromatin remodeling protein HELLS is critical for retinoblastoma tumor initiation and progression. *Oncogene* **9**, 25 (2020).
55. Yao, Y., Liu, S., Biwsen, V., Geiman, T. M. & Muegge, K. Treatment of breast cancer cells with DNA demethylating agents leads to a release of Pol II stalling at genes with DNA-hypermethylated regions upstream of TSS. *Nucleic Acids Res.* **39**, 9508–9520 (2011).
56. He, X. et al. Chromatin remodeling factor LSH drives cancer progression by suppressing the activity of fumarate hydratase. *Cancer Res.* **76**, 5743–5753 (2016).
57. Robinson, M. H. et al. Upregulation of the chromatin remodeler HELLS is mediated by YAP1 in Sonic Hedgehog Medulloblastoma. *Sci. Rep.* **9**, 13611 (2019).
58. Lee, D. W. et al. Proliferation-associated SNF2-like gene (PASG): a SNF2 family member altered in leukemia. *Cancer Res.* **60**, 3612–3622 (2000).
59. Myant, K. et al. LSH and CBH/GLP complex are required for developmentally programmed DNA methylation. *Genome Res.* **21**, 83–94 (2011).
60. Myant, K. & Stancheva, I. LSH cooperates with DNA methyltransferases to repress transcription. *Mol. Cell. Biol.* **28**, 215–226 (2008).
61. Gordon, S., Akopyan, G., Garban, H. & Bonavida, B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. *Oncogene* **25**, 1112–1144 (2006).
62. Kleman, E., Jia, H., Loguercio, S., Su, A. I. & Feeney, A. J. YY1 plays an essential role at all stages of B-cell differentiation. *Proc. Natl Acad. Sci. USA* **113**, E3911–E3920 (2016).
63. Affar, el. B. et al. Essential dosage-dependent functions of the transcription factor yin yang 1 in late embryonic development and cell cycle progression. *Mol. Cell. Biol.* **26**, 3565–3581 (2006).
64. Potluri, V. et al. Transcriptional repression of Bim by a novel YY1-RelA complex is essential for the survival and growth of Multiple Myeloma. *PLoS ONE* **8**, e66121 (2013).
65. Antonio-Andres, G. et al. Role of Yin Yang-1 (YY1) in the transcription regulation of the multi-drug resistance (MDR1) gene. *Leuk. Lymphoma* **59**, 2626–2638 (2018).
66. Corts, J. R. et al. RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis. *Cancer Cell* **33**, 259–273 (2018). e17.
67. Abate, F. et al. Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. *Proc. Natl Acad. Sci. USA* **114**, 764–769 (2017).
68. Brox, M., Haas, K., Moll, L. & Grabbe, S. RhoA as a key regulator of innate and adaptive immunity. *Cell* **8**, 733 (2019).
69. Cools, J. RHOA mutations in peripheral T cell lymphoma. *Nat. Genet.* **46**, 320–321 (2014).
70. Nagata, Y. et al. Vaneregated RHOA mutations in adult T-cell leukemia/lymphoma. *Blood* **127**, 596–604 (2016).
71. Palomero, T. et al. Recurrent mutations in epigenetic regulators, RHOA and PKN kinase in peripheral T cell lymphomas. *Nat. Genet.* **46**, 166–170 (2014).
72. Chen, C. H. et al. Describing the transcriptional complex critical for RhoA gene expression and cancer metastasis. *Nat. Cell Biol.* **12**, 457–467 (2010).
73. Canovas Nunes, S. et al. The small GTPase RhoA lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma. *Blood* **130**, 20 (2018).
74. Schiavone, D., Dewilde, S., Vallania, F., Turkson, J., Di Cunto, F. & Poli, V. The RhoU/Wrch1 Rho GTPase gene is a common transcriptional target of both the gp130/STAT3 and Wnt-1 pathways. *Biochem. J.* **421**, 283–292 (2009).
75. Svensmark, J. H. & Brakebusch, C. Rho GTases in cancer: friend or foe? *Oncoogene* **38**, 7447–7456 (2019).